Skip to main content
In stock|Immunotherapy (Investigational Checkpoint)

Volrustomig

Oncology TypeSolid Tumour
Drug Class / MechanismBispecific Checkpoint Antibody, PD-1 x CTLA-4
No Image
Description

Volrustomig is classified as a Bispecific Checkpoint Antibody, PD-1 x CTLA-4, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational Checkpoint)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3